Arginase Reciprocally Regulates Nitric Oxide Synthase Activity and Contributes to Endothelial Dysfunction in Aging Blood Vessels

Circulation

Volumn 108, Issue 16, 2003, Pages 2000-2006

  Berkowitz, Dan E ^a   White, Ron ^a   Li, Dechun ^a   Minhas, Khalid M ^a   Cernetich, Amy ^a   Kim, Soonyul ^a   Burke, Sean ^a   Shoukas, Artin A ^a   Nyhan, Daniel ^a   Champion, Hunter C ^a   Hare, Joshua M ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Aging; Cardiovascular diseases; Endothelium; Nitric oxide

Indexed keywords

(2 BORONOETHYL)CYSTEINE; 1H OXADIAZOLE QUINOXALIN 1 ONE; ARGINASE; ARGININE; CYCLIC GMP; EFLORNITHINE; ENZYME INHIBITOR; GUANYLATE CYCLASE INHIBITOR; N HYDROXYNORARGININE; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG; CELL RECEPTOR; GUANYLATE CYCLASE; SOLUBLE GUANYLYL CYCLASE; VASODILATOR AGENT;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME REGULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; VASCULAR RING; VASODILATATION; ANIMAL; BLOOD VESSEL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; IN VITRO STUDY; METABOLISM; NASA DISCIPLINE CARDIOPULMONARY; NASA PROGRAM BIOMEDICAL RESEARCH AND COUNTERMEASURES; NON-NASA CENTER; PATHOLOGY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM; WISTAR RAT;

NASA DISCIPLINE CARDIOPULMONARY; NASA PROGRAM BIOMEDICAL RESEARCH AND COUNTERMEASURES; NON-NASA CENTER;

AGING; ANIMALS; ARGINASE; ARGININE; BLOOD VESSELS; CYCLIC GMP; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GUANYLATE CYCLASE; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; VASODILATION; VASODILATOR AGENTS;

EID: 0142023863     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000092948.04444.C7     Document Type: Article

References (34)

1. Cooke JP, Dzau J, Creager A. Endothelial dysfunction in hypercholesterolemia is corrected by L-arginine. Basic Res Cardiol. 1991;86: 173-181.
2. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153-2157.
3. Wu G, Meininger CJ. Arginine nutrition and cardiovascular function. J Nutr. 2000;130:2626-2629.
4. Su Y, Couch M, Block ER. Substrate inhibition of nitric oxide synthase in pulmonary artery endothelial cells in culture. Nitric Oxide. 1997;1: 469-475.
5. Cernadas MR, Sanchez de Miguel L, Garcia-Duran M, et al. Expression of constitutive and inducible nitric oxide synthases in the vascular wall of young and aging rats. Circ Res. 1998;83:279-286.
6. Hecker M, Nematollahi H, Hey C, et al. Inhibition of arginase by NG-hydroxy-L-arginine in alveolar macrophages: implications for the utilization of L-arginine for nitric oxide synthesis. FEBS Lett. 1995;359: 251-254.
7. Lakatta EG. Cardiovascular regulatory mechanisms in advanced age. Physiol Rev. 1993;73:413-467.
8. Brooks-Asplund EM, Shoukas AA, Kim SY, et al. Estrogen has opposing effects in obese, insulin resistant male Zucker rats. J Appl Physiol. 2002;92:2035-2044.
9. Zieman SJ, Gerstenblith G, Lakatta EG, et al. Upregulation of the nitric oxide-cGMP pathway in aged myocardium: physiological response to L-arginine. Circ Res. 2001;88:97-102.
10. Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ, et al. Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction. Biochem Biophys Res Commun. 2001;283:923-927.
11. Ignarro LJ, Buga GM, Wei LH, et al. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A. 2001;98:4202-4208.
12. Colleluori DM, Ash DE. Classical and slow-binding inhibitors of human type II arginase. Biochemistry. 2001;40:9356-9362.
13. Cox JD, Kim NN, Traish AM, et al. Arginase-boronic acid complex highlights a physiological role in erectile function. Nat Struct Biol. 1999; 6:1043-1047.
14. Tenu JP, Lepoivre M, Moali C, et al. Effects of the new arginase inhibitor N(omega)-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide. 1999;3:427-438.
15. Kurz S, Harrison DG. Insulin and the arginine paradox. J Clin Invest. 1997;99:369-370.
16. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336:1-17.
17. Grody WW, Dizikes GJ, Cederbaum SD. Human arginase isozymes. Isozymes Curr Top Biol Med Res. 1987;13:181-214.
18. Griffith OW, Stuehr DJ. Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol. 1995;57:707-736.
19. Reczkowski RS, Ash DE. Rat liver arginase: kinetic mechanism, alternate substrates, and inhibitors. Arch Biochem Biophys. 1994;312:31-37.
20. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethyl-arginine (ADMA): a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation. 1998;98:1842-1847.
21. Chou TC, Yen MH, Li CY, et al. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension. 1998;31: 643-648.
22. Kung CF, Luscher TF. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension. 1995;25: 194-200.
23. Ruetten H, Zabel U, Linz W, et al. Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res. 1999;85:534-541.
24. Taddei S, Virdis A, Ghiadoni L, et al. Age-related reduction of NO availability and oxidative stress in humans. Hypertension. 2001;38: 274-279.
25. Closs EI, Scheld JS, Sharafi M, et al. Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters. Mol Pharmacol. 2000;57:68-74.
26. McDonald KK, Zharikov S, Block ER, et al. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "arginine paradox." J Biol Chem. 1997;272: 31213-31216.
27. Ratajczak P, Damy T, Heymes C, et al. Caveolin-1 and -3 dissociations from caveolae to cytosol in the heart during aging and after myocardial infarction in rat. Cardiovasc Res. 2003;57:358-369.
28. Meurs H, Hamer MA, Pethe S, et al. Modulation of cholinergic airway reactivity and nitric oxide production by endogenous arginase activity. Br J Pharmacol. 2000;130:1793-1798.
29. Kepka-Lenhart D, Mistry SK, Wu G, et al. Arginase I: a limiting factor for nitric oxide and polyamine synthesis by activated macrophages? Am J Physiol Regul Integr Comp Physiol. 2000;279:R2237-R2242.
30. Li H, Meininger CJ, Hawker JR Jr, et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab. 2001;280:E75-E82.
31. Que LG, George SE, Gotoh T, et al. Effects of arginase isoforms on NO production by nNOS. Nitric Oxide. 2002;6:1-8.
32. Selamnia M, Mayeur C, Robert V, et al. Alpha-difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells. Biochem Pharmacol. 1998;55:1241-1245.
33. Zhang C, Hein TW, Wang W, et al. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J. 2001;15:1264-1266.
34. Reisser D, Onier-Cherix N, Jeannin JF. Arginase activity is inhibited by L-NAME, both in vitro and in vivo. J Enzyme Inhib Med Chem. 2002; 17:267-270.